Literature DB >> 16897746

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.

Anna Bergamaschi1, Young H Kim, Pei Wang, Therese Sørlie, Tina Hernandez-Boussard, Per E Lonning, Robert Tibshirani, Anne-Lise Børresen-Dale, Jonathan R Pollack.   

Abstract

Breast cancer is a leading cause of cancer-death among women, where the clinicopathological features of tumors are used to prognosticate and guide therapy. DNA copy number alterations (CNAs), which occur frequently in breast cancer and define key pathogenetic events, are also potentially useful prognostic or predictive factors. Here, we report a genome-wide array-based comparative genomic hybridization (array CGH) survey of CNAs in 89 breast tumors from a patient cohort with locally advanced disease. Statistical analysis links distinct cytoband loci harboring CNAs to specific clinicopathological parameters, including tumor grade, estrogen receptor status, presence of TP53 mutation, and overall survival. Notably, distinct spectra of CNAs also underlie the different subtypes of breast cancer recently defined by expression-profiling, implying these subtypes develop along distinct genetic pathways. In addition, higher numbers of gains/losses are associated with the "basal-like" tumor subtype, while high-level DNA amplification is more frequent in "luminal-B" subtype tumors, suggesting also that distinct mechanisms of genomic instability might underlie their pathogenesis. The identified CNAs may provide a basis for improved patient prognostication, as well as a starting point to define important genes to further our understanding of the pathobiology of breast cancer. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16897746     DOI: 10.1002/gcc.20366

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  202 in total

1.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Authors:  Lisa A Carey; Hope S Rugo; P Kelly Marcom; Erica L Mayer; Francisco J Esteva; Cynthia X Ma; Minetta C Liu; Anna Maria Storniolo; Mothaffar F Rimawi; Andres Forero-Torres; Antonio C Wolff; Timothy J Hobday; Anastasia Ivanova; Wing-Keung Chiu; Madlyn Ferraro; Emily Burrows; Philip S Bernard; Katherine A Hoadley; Charles M Perou; Eric P Winer
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.

Authors:  Jason I Herschkowitz; Wei Zhao; Mei Zhang; Jerry Usary; George Murrow; David Edwards; Jana Knezevic; Stephanie B Greene; David Darr; Melissa A Troester; Susan G Hilsenbeck; Daniel Medina; Charles M Perou; Jeffrey M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-01       Impact factor: 11.205

Review 3.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

4.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

5.  CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.

Authors:  Karen Brajão de Oliveira; Roberta Losi Guembarovski; Alda Maria Fiorina Losi Guembarovski; Ana Cristina da Silva do Amaral Herrera; Walter Jorge Sobrinho; Carolina Batista Ariza; Maria Angelica Ehara Watanabe
Journal:  Clin Exp Med       Date:  2012-06-15       Impact factor: 3.984

6.  Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation.

Authors:  Bing Liu; Lin Liu; Anna Tsykin; Gregory J Goodall; Jeffrey E Green; Min Zhu; Chang Hee Kim; Jiuyong Li
Journal:  Bioinformatics       Date:  2010-10-17       Impact factor: 6.937

Review 7.  PIM1: a promising target in patients with triple-negative breast cancer.

Authors:  Wen Zhao; RuiYue Qiu; Pan Li; Jin Yang
Journal:  Med Oncol       Date:  2017-07-18       Impact factor: 3.064

8.  A sparse Ising model with covariates.

Authors:  Jie Cheng; Elizaveta Levina; Pei Wang; Ji Zhu
Journal:  Biometrics       Date:  2014-08-05       Impact factor: 2.571

9.  Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance.

Authors:  Li Zhang; Yoshitsugu Mitani; Carlos Caulin; Pulivarthi H Rao; Merrill S Kies; Pierre Saintigny; Nianxiang Zhang; Randal S Weber; Scott M Lippman; Adel K El-Naggar
Journal:  Am J Pathol       Date:  2013-04-10       Impact factor: 4.307

10.  A systems approach to analysis of molecular complexity in breast cancer.

Authors:  Bryan T Hennessy; Ana Maria Gonzalez-Angulo; Mark S Carey; Gordon B Mills
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.